Hepatitis B
No Tenofovir Resistance Seen In 2 Years of Hepatitis B Treatment
- Details
- Category: Approved HBV Drugs
- Published on Friday, 27 June 2014 00:00
- Written by Liz Highleyman
No cases of resistance to tenofovir (Viread) were detected among chronic hepatitis B patients with prior resistance to lamivudine (3TC or Epivir) through 96 weeks of treatment, according to a study described in the June 11 advance edition of Clinical Gastroenterology and Hepatology. Adding emtricitabine (Emtriva) did not improve effectiveness compared with tenofovir alone.
Antiviral Treatment for Hepatitis B Lowers Risk of Liver Cancer
- Details
- Category: HBV Treatment
- Published on Thursday, 19 June 2014 00:00
- Written by Liz Highleyman
Antiviral therapy for chronic hepatitis B virus (HBV) infection can reduce the risk of developing hepatocellular carcinoma (HCC), even among people with high HBV viral load, according to research described in the May 2014 edition of Clinical Gastroenterology and Hepatology.
DDW 2014: Some Hepatitis B Patients Can Stop Antiviral Treatment without Relapse
- Details
- Category: HBV Treatment
- Published on Tuesday, 06 May 2014 00:00
- Written by Liz Highleyman
Stopping antiviral therapy after several years appears generally safe for people with HBeAg negative chronic hepatitis B without liver cirrhosis, and a substantial proportion do not experience viral relapse or worsening liver inflammation while off treatment, according to a pair of posters presented at the Digestive Disease Week (DDW 2014) meeting this week in Chicago.
Screening and Post-Natal Prophylaxis Reduce Mother-to-Child HBV Transmission
- Details
- Category: Pregnancy & HBV MTCT
- Published on Wednesday, 11 June 2014 00:00
- Written by Liz Highleyman
Prenatal screening of pregnant women for hepatitis B virus (HBV), followed by immune prophylaxis for infants using injected hepatitis B antibodies and the first dose of the HBV vaccine given soon after delivery, resulted in a low rate of vertical HBV transmission -- less than 1 per 100 births -- in a real-world study described in the May 27 advance edition of Annals of Internal Medicine.
May Is Hepatitis Awareness Month
- Details
- Category: HBV Treatment
- Published on Friday, 02 May 2014 00:00
- Written by HIVandHepatitis.com
May is Hepatitis Awareness Month in the U.S., an opportunity to promote better understanding of viral hepatitis and to encourage more people to get tested and receive care for hepatitis B and C. Hepatitis Testing Day is coming up on May 19.
Prevention Task Force Recommends Hepatitis B Screening for People at High Risk
- Details
- Category: HBV Testing & Diagnosis
- Published on Wednesday, 04 June 2014 00:00
- Written by HIVandHepatitis.com
The U.S. Preventive Services Task Force (USPSTF) last week issued a new recommendation for hepatitis B virus (HBV) screening of non-pregnant adolescents and adults without current symptoms of viral hepatitis. The task force called for screening of people at high risk for infection including people with HIV, gay and bisexual men, and people who inject drugs.
EASL 2014: Long-term Tenofovir Maintains Viral Suppression in People with Hepatitis B
- Details
- Category: HBV Treatment
- Published on Friday, 02 May 2014 00:00
- Written by Liz Highleyman
Treatment with tenofovir (Viread) for 3 years remained effective in keeping hepatitis B virus (HBV) suppressed, normalizing liver inflammation, and potentially reducing liver disease progression, according to studies from Germany, France, and Spain presented at the 49thEASL International Liver Congress (EASL 2014) recently held in London.
DDW2014: Coverage of Digestive Disease Week 2014
- Details
- Category: HBV Treatment
- Published on Saturday, 31 May 2014 00:00
- Written by Liz Highleyman
HIVandHepatitis.com coverage of the 2014 Digestive Disease Week annual meeting (DDW 2014) in Chicago, May 3-6, 2014.
Hepatitis C
New Hepatitis C Treatments Highlighted at Digestive Disease Week
Some Negative Predictive Factors Do Not Impair Response to Faldaprevir
AbbVie Interferon-free Regimen Cures More than 90% of Hepatitis C Patients
Sustained Response to Interferon Is Durable in Children with Hepatitis C
HIV/HCV Coinfection
Some Negative Predictive Factors Do Not Impair Response to Faldaprevir
Hepatitis B
Outcomes in HBV/HCV Coinfected People Depend on Which Virus Dominates
Some Hepatitis B Patients Can Stop Antiviral Treatment Without Relapse
Complications and Related Conditions
Rifaximin May Be Beneficial for People with Advanced Liver Cirrhosis
Drinking More Coffee Is Associated with Less Liver Fibrosis
EASL 2014: Sci-B-Vac Bests Engerix-B for Preventing Mother-to-Child HBV Transmission
- Details
- Category: HBV Vaccines
- Published on Tuesday, 29 April 2014 00:00
- Written by Liz Highleyman
An investigational vaccine known as Sci-B-Vac given to babies born to women with hepatitis B was more effective at preventing HBV infection than the widely used Engerix-B vaccine, according to a report at the EASL International Liver Congress this month in London.
More Articles...
- EASL 2014: Prolonged Pegylated Interferon + Tenofovir Does Not Prevent Hepatitis Delta Relapse
- EASL 2014: Adding Interferon to Antivirals May Improve Response for Hepatitis B Patients
- EASL 2014: New Research Sheds Light on Liver Cancer Diagnosis, Staging, and Treatment
- EASL 2014: International Liver Congress Starts this Week in London
- U.S. Government Releases Updated Viral Hepatitis Action Plan